Literature DB >> 31207301

Dietary supplementation with polypeptides improved growth performance, antibacterial immune and intestinal microbiota structure of Litopenaeus vannamei.

Xu-Zheng Liao1, Shi-Kang Hu1, Bo Wang1, Hai-Peng Qin1, Ji-Chen Zhao1, Zi-Hao He1, Xie-Yan Chen1, Yong-Sheng Liu2, Peng Qu3, Cheng-Bo Sun4, Shuang Zhang5.   

Abstract

Antibacterial peptides (AMPs) are expected to replace some or all of the antibiotics and become a new feed additive. However, the high production cost and unclear mechanism limited the application of AMPs. In this research, the effects of a commercial polypeptide (Polypeptide S100) whose main components are AMPs on the growth, antibacterial immune and intestinal microbial of Litopenaeus vannamei were study. L. vannamei (initial weight of 0.16 ± 0.03 g) were fed for 123 days with basal diet added Polypeptide S100 at two levels each (0.5% and 1%) as experimental groups, and a basal diet as control. Dietary inclusion of Polypeptide S100 at 1% level significantly increased the weight gain (WG) and specific growth rate (SGR) of L. vannamei. The survival rates of L. vannamei in 0.5% and 1% Polypeptide S100 groups were significantly higher than the control when infected by Vibrio harveyi but not Vibrio parahaemolyticus. The activities of total superoxide dismutase (T-SOD) and lysozyme (LZM) in the two experimental groups were all significantly higher than the control. Differently, the activities of amylase (AMS) and lipase (LPS) were significantly higher in 0.5% Polypeptide S100 group but lower in 1.0% Polypeptide S100 group. Illumina MiSeq high-throughput sequencing showed that the dominant phyla in the intestine of L. vannamei were Proteobacteria, followed by Actinobacteria, Bacteroidetes, Chloroflexi, Cyanobacteria, Fusobacteria and Tenericutes, and the abundance of predominant phyla Cyanobacteria were upregulated significantly in the experimental groups. At the family level, significant increase was observed in Pseudomonadaceae and Xanthomonadaceae but decrease in Vibrionaceae in the 1.0% Polypeptide S100 group. The abundance of predominant genus Photobacterium were obviously downregulated in the two experimental groups. Unlikely, the abundance of Pseudomonas and Stenotrophomonas were distinctly increased in the 1.0% Polypeptide S100 group but not significantly different from the control in 0.5% Polypeptide S100 group. All these results suggested that Polypeptide S100 could improve the growth performance, antibacterial immune and intestinal microbiota structure of L. vannamei.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Antibacterial immune; Growth performance; Intestinal microbiota; Litopenaeus vannamei; Polypeptide

Mesh:

Substances:

Year:  2019        PMID: 31207301     DOI: 10.1016/j.fsi.2019.06.033

Source DB:  PubMed          Journal:  Fish Shellfish Immunol        ISSN: 1050-4648            Impact factor:   4.581


  4 in total

Review 1.  Fermented natural product targeting gut microbiota regulate immunity and anti-inflammatory activity: A possible way to prevent COVID-19 in daily diet.

Authors:  Quancen Li; Na Li; Wenwen Cai; Meifang Xiao; Bin Liu; Feng Zeng
Journal:  J Funct Foods       Date:  2022-08-22       Impact factor: 5.223

Review 2.  Effects of intestinal microbiota on physiological metabolism and pathogenicity of Vibrio.

Authors:  Han Sun; Changliang Zhu; Xiaodan Fu; Shakir Khattak; Jingyu Wang; Zhihao Liu; Qing Kong; Haijin Mou; Francesco Secundo
Journal:  Front Microbiol       Date:  2022-08-23       Impact factor: 6.064

3.  Response of hemocytes profile in the black tiger shrimp (Penaeus monodon) against Vibrio harveyi induced by Xylocarpus granatum leaves extract.

Authors:  Gina Saptiani; A Syafei Sidik; Fikri Ardhani; Esti Handayani Hardi
Journal:  Vet World       Date:  2020-04-22

4.  Integrated Analysis of mRNA-Seq and MiRNA-Seq Reveals the Molecular Mechanism of the Intestinal Immune Response in Marsupenaeus japonicus Under Decapod Iridescent Virus 1 Infection.

Authors:  Zihao He; Yunqi Zhong; Danqing Hou; Xianye Hu; Zhibin Fu; Luyao Liu; Shuang Zhang; Chengbo Sun
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.